
PneumoWave
Powering the future diagnosis, monitoring and treatment of respiratory illness.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor investor investor investor investor | €0.0 | round | |
* | £7.5m | Series A | |
Total Funding | 000k |
USD | 2022 | 2023 |
---|---|---|
Revenues | 0000 | 0000 |
% growth | - | 110 % |
EBITDA | 0000 | 0000 |
Profit | 0000 | 0000 |
EV | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x |
R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
PneumoWave operates in the healthcare sector, focusing on the diagnosis, monitoring, and treatment of respiratory illnesses. The company provides an advanced respiratory monitoring platform that integrates longitudinal patient data, biomarkers, machine learning, and data science. This end-to-end solution offers real-time physiological data and patient-centric biomarkers, enabling clinicians, researchers, and patients to predict, monitor, detect, and alert to respiratory adverse events both in hospitals and at home. PneumoWave's business model leverages these insights to aid in the discovery and development of novel treatments with enhanced therapeutic potential and safety. By unlocking multiple business models, the company serves a diverse clientele, including healthcare providers, researchers, and patients, aiming to improve efficiency and outcomes in respiratory care. Keywords: respiratory, monitoring, AI-driven, biomarkers, patient data, healthcare, treatment, real-time, physiological, safety.